Original paperpolyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice
References (30)
- et al.
Effect of endocrine therapy on growth T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II)
Eur J Cancer
(1993) - et al.
Estrogen and progesterone regulate secretion of insulin-like growth factor binding proteins by human breast cancer cells
Biochem Biophys Res Commun
(1993) - et al.
Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid, isolation of two forms with different biological actions
J Biol Chem
(1988) - et al.
Pharmacokinetic profile of recombinant human insulin-like growth factor binding protein-1 in athymic mice
Biomed Pharmacother
(1996) - et al.
Analysis of serum insulin-like growth factor binding proteins using Western blotting; use of the method for titration of the binding proteins and competitive binding studies
Anal Biochem
(1986) - et al.
Growth hormone dependent insulin-like growth factor binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in human skin fibroblasts
Biochem Biophys Res Commun
(1988) - et al.
Estrogen regulation of the estrogen receptor and insulin-like growth factor-I in the rat uterus: a potential role of coupling between effects of estrogen and IGF
Steroids
(1994) Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine
Fertil Steril
(1994)- et al.
Insulin-like growth factors and cancer
Ann Intern Med
(1995) Oncogenes and the strategy of growth factors
Cell
(1994)
Stimulatory effects of insulin and insulin-like growth factor on migration and tube formation by vascular endothelial cells
Atherosclerosis
Insulin-like growth factor I as an angiogenic agent
Ann NY Acad Sci
Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts
Mol Cell Biol
The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo
Cancer Res
Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function
Cancer Res
Cited by (52)
Airway smooth muscle cells are insensitive to the anti-proliferative effects of corticosteroids: The novel role of insulin growth factor binding Protein-1 in asthma
2019, ImmunobiologyCitation Excerpt :Several studies investigated the role of IGFBP1 in modulating cell growth. For instance, IGFBP-1 decreases the growth of breast cancer cells in response to estrogen and serum (Van den Berg et al., 1997) and the thymidine uptake in rat aortic smooth muscle cells (Motani et al., 1995). Evidence suggests that IGFBP-1 downregulates the expression of key proteins associated with cell growth such as ERK and AKT in fibroblasts (Prokop et al., 2013).
Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics
2018, Cancer Treatment ReviewsCitation Excerpt :In addition, some IGFBPs may exert their anti-tumor activities via an IGF-1-independent manner [39,40], however may also prolong the IGF-1 induced signal transduction via partial ligand release. It has been previously addressed that both exogenous and endogenous IGFBP1 may suppress the IGF-1 induced motility and growth of breast tumors in vitro and in athymic mice [41–44]. In contrast to IGFBP1, IGFBP2 is considered to have oncogenic activities in breast and other malignancies, although results remain conflicting [45].
Indole-3-Carbinol disrupts Estrogen Receptor-alpha dependent expression of Insulin-like Growth Factor-1 Receptor and Insulin Receptor Substrate-1 and proliferation of human breast cancer cells
2012, Molecular and Cellular EndocrinologyCitation Excerpt :Elucidation of the IGF1 receptor activated signaling cascade and its role in controlling proliferation of breast cancer cells has influenced the development of several therapeutic strategies that target this pathway. One approach has been to disrupt IGF1 binding to IGF1R, either by employing neutralizing monoclonal antibodies directed against IGF1, or by increasing levels of IGF binding proteins (IGFBP), which naturally bind and sequester IGF1 (Goya et al., 2004; Van den Berg et al., 1997). In a complementary manner, monoclonal antibodies can be directed toward IGF1R to induce receptor-mediated endocytosis, followed by proteolytic degradation (Lee et al., 2003; Sachdev et al., 2003; Wang et al., 2005).
Defining the pathway to insulin-like growth factor system targeting in cancer
2010, Biochemical PharmacologyRole of insulin-like growth factor-1R system in colorectal carcinogenesis
2008, Critical Reviews in Oncology/HematologyCitation Excerpt :Also, co-injection of cells expressing 486/STOP with wild-type tumor cells inhibited the growth of wild-type tumor cells secondary to a bystander effect [50]. IGF binding proteins (IGFBP-1 and IGFBP-3) are also being investigated as possible anticancer agents [51,52]. The IGF system plays an important role in tumorigenesis and has been shown to be an absolute requirement for the establishment and maintenance of the transformed phenotype [53].
The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models
2005, Cytokine and Growth Factor Reviews